Similar articles for PMID: 31014065

Year	Number of Results
2016	4
2017	13
2018	32
2019	61
2020	57
2021	30
2022	18
2023	11
2024	0

1

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors.

Lee KA, Kim HR, Yoon SY. Lee KA, et al. Korean J Intern Med. 2019 Nov;34(6):1197-1209. doi: 10.3904/kjim.2019.060. Epub 2019 Apr 25. Korean J Intern Med. 2019. PMID: 31014065 Free PMC article. Review.

2

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM. Kostine M, et al. Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16. Ann Rheum Dis. 2018. PMID: 29146737

3

[Rheumatological complications of immune checkpoint inhibitor therapy].

Lazarou I, Fernandez E. Lazarou I, et al. Rev Med Suisse. 2020 Mar 11;16(685):504-507. Rev Med Suisse. 2020. PMID: 32167253 Review. French.

4

Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Leipe J, Mariette X. Leipe J, et al. Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii49-vii58. doi: 10.1093/rheumatology/kez360. Rheumatology (Oxford). 2019. PMID: 31816078 Free PMC article. Review.

5

Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E. Narváez J, et al. Autoimmun Rev. 2018 Oct;17(10):1040-1045. doi: 10.1016/j.autrev.2018.05.002. Epub 2018 Aug 10. Autoimmun Rev. 2018. PMID: 30103042 Review.

6

Rheumatic immune-related adverse events from cancer immunotherapy.

Calabrese LH, Calabrese C, Cappelli LC. Calabrese LH, et al. Nat Rev Rheumatol. 2018 Oct;14(10):569-579. doi: 10.1038/s41584-018-0074-9. Nat Rev Rheumatol. 2018. PMID: 30171203 Review.

7

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S. Mitchell EL, et al. Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13. Eur J Cancer. 2018. PMID: 30439628

8

Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.

Weinmann SC, Pisetsky DS. Weinmann SC, et al. Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii59-vii67. doi: 10.1093/rheumatology/kez308. Rheumatology (Oxford). 2019. PMID: 31816080 Free PMC article. Review.

9

Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?

Gediz F, Kobak S. Gediz F, et al. Curr Rheumatol Rev. 2019;15(3):201-208. doi: 10.2174/1573397115666190119094736. Curr Rheumatol Rev. 2019. PMID: 30659547 Review.

10

Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.

Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC. Liew DFL, et al. Int J Rheum Dis. 2019 Feb;22(2):297-302. doi: 10.1111/1756-185X.13444. Epub 2018 Nov 22. Int J Rheum Dis. 2019. PMID: 30549256

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

194 results

Results by year